Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Paola Mapelli, Samuele Ghezzo, Ana Maria Samanes Gajate, Erik Preza, Giorgio Brembilla, Vito Cucchiara, Naghia Ahmed, Carolina Bezzi, Luca Presotto, Valentino Bettinardi, Annarita Savi, Patrizia Magnani, Raffaele Menichini, Angela Coliva, Ilaria Neri, Ettore Di Gaeta, Luigi Gianolli, Massimo Freschi, Alberto Briganti, Francesco De Cobelli, Paola Scifo, Maria Picchio
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
hybrid imaging
PET/MRI
PSMA
RM2
prostate cancer
multimodal imaging
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/4ecd835d579a4984862cb5adb3863929
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing <sup>68</sup>Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with <sup>68</sup>Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, <sup>68</sup>Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by <sup>68</sup>Ga-PSMA, and <sup>68</sup>Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.

Ejemplares similares